Vice says that as medical use of hallucinogens gets closer, “Doctors won’t be writing prescriptions for mushroom caps or stems:“
The mushrooms “aren’t expensive to produce. But researchers have to source their psilocybin from highly regulated labs because natural products vary, and researchers need consistency in chemical composition and dosage in order to do controlled studies. Clinicians need to know how much of a drug they’re giving to a patient, how long it takes to kick in, and how long it lasts; they also need to be sure their drug isn’t tainted with other chemicals. It also helps to be able to mass-produce large amounts and not be threatened by variables, like weather, that affect agricultural products.
In other cutting-edge drug news:
- Research firm Green Horizons found strong demand for psychedelics.
- Oregon’s ballot initiative to create a psilocybin therapy program appears likely to make the November ballot.
- Also in Canna Law Blog, a look at ketamine clinics and corporate medicine in California.
